INVA 8002
Alternative Names: INVA-8002Latest Information Update: 09 Dec 2022
At a glance
- Originator InveniAI; PRISM BioLab
- Developer Invea Therapeutics
- Class Anti-inflammatories; Irritable bowel syndrome therapies; Peptidomimetics; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Irritable bowel syndrome; Ulcerative colitis
Most Recent Events
- 09 Dec 2022 Phase-I clinical trials in Irritable bowel syndrome in USA (unspecified route)
- 09 Dec 2022 Phase-I clinical trials in Ulcerative colitis (Adjunctive treatment) in USA prior to December 2022 (unspecified route)
- 26 Jul 2021 InveniAI anticipates that INVA 8001 will be IND ready by H1 of 2022 (InveniAI pipeline, July 2021)